arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

REGENTIS BIOMATERIALS LTD.

RGNT

$1.40 ▲ +0.02 (+1.45%) at close

4 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

REGENTIS BIOMATERIALS LTD. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -116.0% ↘

FCF / Share $-2.43 ↘

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity 0.25

info Valuation on last close. End-of-day price, Nov 4, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-13.65M

↓ -384.3% —

FCF / Share Free cash flow per share

$-2.43

↓ -946.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
FCF Growth YoY (%)	-946.9% Weak Weak Year-over-year change in free cash flow	96.7% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
FCF / Net Income (x)	0.10x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.30x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Return on Invested Capital (%)	-116.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	3.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-91.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	193.4% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-287.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2018%)	-11.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-178%)	9.0% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-40%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Debt to Equity (x)	0.25x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-58%)	-0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-102%)	-0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	—
Interest Coverage (x)	-88.20x Weak Weak Operating income divided by interest expense Optimal: > 5x	93.20x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-6.18M	$573.00K	$325.00K	—
Debt / EBITDA (x)	-0.17x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.61x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.17x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Basic EPS, GAAP (USD)	$-24.16	$1.72	$-24.09	—
Free Cash Flow per Share (USD)	$-2.43	$-0.23	$-7.03	—
Book Value per Share (USD)	$0.92	$-253.42	$-264.57	—
Tangible Book Value per Share (USD)	$0.92	$-253.42	$-264.57	—
Basic Weighted Avg Shares (shares)	566,744	2.77M	173,508	—

🏦 How resilient is the balance sheet? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Total Equity (USD)	$4.74M	$-41.10M	$-45.91M	$-42.06M

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Net Income, GAAP (USD)	$-13.65M	$4.80M	$-4.13M	—
Operating Cash Flow (USD)	$-1.38M	$-641.00K	$-1.22M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 4 quarters

REGENTIS BIOMATERIALS LTD.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RGNT with peers